Navigation Links
Yuma Therapeutics Awarded a Research Grant by the Alzheimer's Drug Discovery Foundation to Develop Novel Therapeutics for Alzheimer's Disease
Date:3/28/2011

NEW YORK, March 28, 2011 /PRNewswire-USNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF) announced today that it has awarded a grant of $249,810 to Yuma Therapeutics Corporation (Yuma) to develop small molecules to treat Alzheimer's disease.

(Logo: https://photos.prnewswire.com/prnh/20090805/DC57332LOGO)

The award will fund work to develop Yuma's innovative disease-modifying pharmaceutical compounds that target neurofibrillary tangles resulting from abnormal forms of the protein tau, which represents a promising new approach with potential to affect disease progression in Alzheimer's disease.

"We are excited to support Yuma Therapeutics innovative program in this area," said Howard Fillit, M.D., executive director of the ADDF.  "Small molecule therapeutics targeting the tau pathway could result in a disease-modifying therapy for Alzheimer's disease."

"We are honored to be selected for this peer-reviewed grant, which recognizes the promise of Yuma's approach to generating novel Alzheimer's disease therapies," said Yukari Y. Perrella, founder and president of Yuma.  "We look forward to interacting with the ADDF team."

About the Alzheimer's Drug Discovery Foundation (www.AlzDiscovery.org)

The ADDF is the only public charity whose sole mission is to accelerate the discovery and development of drugs to prevent, treat and cure Alzheimer's disease, related dementias and cognitive aging. Since 1998, the ADDF has granted more than $45 million to fund over 325 Alzheimer's drug discovery and development programs in academic centers and biotechnology companies in 17 countries. 

About Yuma Therapeutics Corporation (www.yumatherapeutics.com)

Yuma Therapeutics is a privately held biopharmaceutical company focused on developing novel disease-modifying small molecule drugs to treat neurodegenerative diseases.  The Company is developing pharmaceutical compounds that target the tau pathway, a promising new approach to affect the disease progression of Alzheimer's disease.


'/>"/>
SOURCE Alzheimer's Drug Discovery Foundation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Mersana Therapeutics Initiates Phase 1b Extension Study of XMT-1001 in Gastric Cancer and Non-Small Cell Lung Cancer
2. Reportlinker Adds Therapeutics for Immune System Disorders
3. Tarsa Therapeutics Reports Positive Top-Line Results From Pivotal Phase III ORACAL Trial of its Oral Calcitonin in Treatment of Postmenopausal Osteoporosis
4. Echo Therapeutics Hires Two Seasoned Medical Device and Diagnostics Executives
5. Pervasis Therapeutics Announces Late-Breaking Oral Presentation at American Association for Cancer Research Annual Meeting
6. Echo Therapeutics Announces 2010 Financial Results
7. Nile Therapeutics Reports 2010 Fourth Quarter and Full Year Financial Results
8. Reportlinker Adds Methicillin-Resistant Staphylococcus Aureus (MRSA) Therapeutics - Pipeline Assessment and Market Forecasts to 2017
9. Halozyme Therapeutics Reports Fourth Quarter and Year End 2010 Financial Results
10. Orexigen® Therapeutics Reports Fourth Quarter and Year Ended December 31, 2010 Financial Results
11. PNP Therapeutics Meets Important Financial and Regulatory Objectives in Development of New Cancer Therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... , Feb 23, 2017 Research and Markets has ... - 2016" report to their offering. ... The latest research Menopause Drugs Price Analysis and Strategies ... market. The research answers the following questions: ... attributes? How are they positioned in the Global Menopause market? ...
(Date:2/23/2017)... CITY, Calif. , Feb. 23, 2017 /PRNewswire/ ... pharmaceutical company focused on the development and commercialization ... acute pain, announced that it will release fourth ... on Thursday, March 2nd, 2017. AcelRx management will ... Eastern Time (1:30 p.m. Pacific Time) on March ...
(Date:2/23/2017)... Research and Markets has announced the addition of the "Global ... report to their offering. ... The Global Endoscopy Market is poised to grow at ... approximately $47.6 billion by 2025. This industry report ... on global as well as regional levels presented in the research ...
Breaking Medicine Technology:
(Date:2/23/2017)... ... February 23, 2017 , ... ... clinician-based audience, will be participating in Rare Disease Day events, hosted by the ... addition, Rare Disease Report, a website, weekly e-newsletter and quarterly publication, will be ...
(Date:2/23/2017)... Fair Lawn, NJ (PRWEB) , ... February 23, ... ... specializing in thought leadership , media relations, content marketing, social media ... Vermont. With several clients already in the state and in nearby New Hampshire, ...
(Date:2/23/2017)... ... February 23, 2017 , ... Pink Pig Publishing LLC ... converge and explore the world from different perspectives. By providing a place for ... gain understanding, increase empathy, and find greater happiness. , "Our approach to ...
(Date:2/23/2017)... Lincoln, RI (PRWEB) , ... February 23, 2017 ... ... announced today a new partnership with the Rhode Island Consortium for Autism Research ... provide an opportunity for children with autism spectrum disorder (ASD) to see films ...
(Date:2/23/2017)... ... February 23, 2017 , ... Curemark, LLC announced today ... efficacy of CM-AT in children aged 3-8 with Autism, is now enrolling at three ... enrolling children across the United States. , “There are currently no approved drugs ...
Breaking Medicine News(10 mins):